Gilead announced plans to discontinue the ENHANCE-3 study of magrolimab regimen due to futility and an increased mortality. Credit: Tada Images / Shutterstock.

The US Food and Drug Administration (FDA) has placed a full clinical hold on all the clinical trials of Gilead Sciences‘ magrolimab for myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

This includes related expanded access programmes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Concurrently, Gilead discontinued the Phase III ENHANCE-3 clinical trial of magrolimab in AML patients.

The ENHANCE-3 trial is designed to assess the efficacy and safety of magrolimab plus venetoclax plus azacitidine as against placebo plus venetoclax and azacitidine in recently diagnosed, untreated AML patients who are not eligible to receive intensive chemotherapy.

The decision to halt the study comes after the trial’s independent Data Monitoring Committee reviewed top-line interim analysis trial findings for overall survival (OS) and recommended the discontinuation.

Analysis indicated that magrolimab plus azacitidine and venetoclax proved to be futile and with increased mortality, primarily due to infections and respiratory failure.

These findings, along with data from two other clinical studies in higher-risk MDS (ENHANCE) and AML with TP53 mutations (ENHANCE-2), which also demonstrated futility and higher death risk in the magrolimab-treatment group, led the company to decide against further development of magrolimab in haematologic cancers.

Patients currently enrolled in the ENHANCE-3 study will stop receiving magrolimab treatment.

Gilead also announced plans to report a top-line, integrated summary of all the magrolimab trials, including ENHANCE, ENHANCE-2, and ENHANCE-3, shortly.

The company is currently reviewing the safety profile of magrolimab across all ongoing solid tumour trials and will update this assessment as soon as it is feasible.

Last September, the company announced the termination of a Phase III trial of magrolimab.

The company terminated the ENHANCE-2 trial in AML with TP53 mutations.

Gilead Sciences chief medical officer Merdad Parsey said: “The complexity of treating blood cancer is highlighted in these results.

“We are incredibly grateful to all the patients and investigators for their participation in the ENHANCE studies.”